Orthocell (ASX:OCC) received regulatory approval from Singapore's Health Sciences Authority to market and sell its Striate+ dental membrane for guided bone and tissue regeneration applications in the country, according to a Tuesday filing with the Australian bourse.
The company is on track to receive regulatory clearance for Striate+ in Brazil within three to six months, the filing said.
Shares were up 9% in morning trade Tuesday.